Drug General Information
Drug ID	D0H1FL
Former ID	DIB005906
Drug Name	PF-514273
Drug Type	Small molecular drug
Indication	Obesity [ICD9: 278; ICD10:E66]		Discontinued in Phase 1	[548445]
Company	Pfizer Inc
Structure		Download 2D MOL 3D MOL
Formula	C21H17Cl2F2N3O2
Canonical SMILES	C1(=O)N(CCOc2c1nn(c2c1ccc(cc1)Cl)c1ccccc1Cl)CC(F)(F)C
PubChem Compound ID	11316919
Target and Pathway
Target(s)	Cannabinoid receptor 1	Target Info	Modulator	[532853]
KEGG Pathway	Rap1 signaling pathway
	Neuroactive ligand-receptor interaction
	Retrograde endocannabinoid signaling
PANTHER Pathway	Endogenous cannabinoid signaling
Pathway Interaction Database	N-cadherin signaling events
Reactome	Class A/1 (Rhodopsin-like receptors)
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Small Ligand GPCRs
	BDNF signaling pathway
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 548445	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025584)
Ref 532853	Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference. Alcohol. 2014 Aug;48(5):427-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.